Background
Hereditary angioedema (HAE) can greatly affect a person’s quality of life. The main goals of treatment are to control the disease and help patients live normally. A medication called garadacimab has shown promise in preventing HAE attacks and improving quality of life.
Study Overview
In a key phase III study, 39 patients received garadacimab, while 25 received a placebo. An extension study included 90 new patients and 71 who had already been treated. All patients aged 18 and older completed a questionnaire to measure their quality of life.
Results
In both studies, about 60% of patients were attack-free. Those on garadacimab showed significant improvements in their quality of life scores compared to those on placebo:
- In the phase III study, attack-free patients improved from an average score of 38.8 to 6.6 after six months.
- Patients with attacks improved from 43.7 to 40.5.
- In the extension study, new patients who became attack-free improved from 46.2 to 8.6 after a year.
- Previous patients maintained their quality of life improvements.
Conclusion
Garadacimab significantly improved the quality of life for patients with HAE, especially for those who were attack-free. This brings them closer to full disease control and a normal life.
Actionable Steps for Clinics and Patients
Define Measurable Outcomes
Set clear goals to achieve attack-free status, which leads to better quality of life.
Select AI Tools
Choose AI solutions that meet specific clinical needs related to managing HAE.
Implement Gradually
Start with a pilot project to track the real-world impact of these solutions on patient outcomes.
Contact Us for AI Solutions
For more information on AI in medical management, reach out to us:
- Telegram: https://t.me/itinai
- X: https://x.com/vlruso
- LinkedIn: https://www.linkedin.com/company/itinai/
